The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pet cancer therapeutics market reached a value of US$ 245.2 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 435.2 Million by 2027, exhibiting a CAGR of 10.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pet cancer therapeutics refer to the diagnosis and treatment alternatives for cancerous and tumor growth in domesticated animals. It involves the treatment of lymphoma, mast cell cancer, melanoma and mammary and squamous cell cancer in dogs, cats and other pet animals. Some of the commonly used therapeutics include chemotherapy, immunotherapy, radiation therapy and biopsy. These therapies gradually neutralize or shrink the cancer cells using plant- and bacteria-based drugs and prevent the tumor from affecting the other parts of the body. The drugs are administered orally or injected intravenously, under the skin or into a muscle or the tumor. They are mixed with the food or treats to mask the flavor and make it more appealing for the pets.
The increasing prevalence of cancer in animals across the globe is one of the key factors driving the growth of the market. Moreover, the rising domestication of animals and increasing concerns regarding pet health among the masses are providing a thrust to the market growth. Leukemia and lymphoma are highly common in cats and certain breeds of aging dogs and can be caused by prolonged exposure to ultraviolet (UV) rays, second-hand tobacco smoke, herbicides, pesticides, insecticides and air pollution. In line with this, the increasing awareness regarding the benefits of timely diagnosis and available treatment alternatives is contributing to the growth of the market. Various technological advancements, such as the development of highly targeted and specific therapies for animal cancer treatment with minimal side effects, are also favoring the market growth. Other factors, including rising expenditure capacities of the consumers on pet healthcare, along with extensive research and development (R&D) activities in the field of veterinary oncology, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pet cancer therapeutics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapy, animal species, cancer type and end user.
Breakup by Therapy:
Breakup by Animal Species:
Breakup by Cancer Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, ELIAS Animal Health LLC, Karyopharm Therapeutics, Pfizer Inc., Regeneus Ltd., Rhizen Pharmaceuticals AG, Torigen Pharmaceuticals Inc., VetDC Inc., Virbac and Zoetis Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Therapy, Animal Species, Cancer Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AB Science, Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, ELIAS Animal Health LLC, Karyopharm Therapeutics, Pfizer Inc., Regeneus Ltd., Rhizen Pharmaceuticals AG, Torigen Pharmaceuticals Inc., VetDC Inc., Virbac and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at